[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540216":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":73,"collaborators":75,"id":83,"slug":20,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":20,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":20,"enrollmentInfo":91,"targetDuration":20,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Each subject will receive LUCAR-20SP cells","EXPERIMENTAL","Chimeric antigen receptor T cells LUCAR-20SP cells",[13],"Biological: LUCAR-20SP cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","LUCAR-20SP cells","Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Yuqin Song","CONTACT","13683398726","songyq22622@163.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Yan Xie","13671376201","xieyan9@263.net",[32,50,60],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Beijing GoBroad Boren Hospital","RECRUITING","Beijing","Beijing Municipality","100070","China",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":47,"role":24,"phone":48,"phoneExt":20,"email":49},"Yajing Zhang","18501333856","zhangyj3@gobroadhealthcare.com",{"facility":5,"status":34,"city":35,"state":36,"zip":51,"country":38,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"100142",{"type":40,"coordinates":53},[42,43],{"lat":43,"lon":42},[56,57,58],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"name":23,"role":59,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":61,"status":34,"city":62,"state":20,"zip":20,"country":38,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Henan Cancer Hospital","Zhengzhou",{"type":40,"coordinates":64},[65,66],113.64861,34.75778,{"lat":66,"lon":65},[69],{"name":70,"role":24,"phone":71,"phoneExt":20,"email":72},"Keshu Zhou","13674902391","drzhouks77@163.com",{"type":74,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[76,79,81],{"name":77,"class":78},"Nanjing Legend Biotech Co.","INDUSTRY",{"name":80,"class":6},"Beijing Boren Hospital",{"name":61,"class":82},"OTHER_GOV","100540216",false,"NCT06313957","A Study of LUCAR-20SP in Subjects With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma","A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-20SP, an Allogenic Chimeric Antigen Receptor(CAR)-T Cell Therapy Targeting CD20 in Subjects With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Subjects voluntarily participate in clinical research;\n* Age ≥18 years old;\n* Eastern Cooperative Oncology Group (ECOG) score 0-1;\n* Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, histologically indolent lymphoma to diffuse large B-cell lymphoma; CD20 positive;\n* At least one measurable tumor lesion according to the Lugano 2014.\n* Expected survival ≥3 months;\n* Clinical laboratory values in the screening period meet criteria.\n* Effective contraception.\n\nExclusion Criteria:\n\n* Prior antitumor therapy with insufficient washout period.\n* Previous treatment with allogeneic cell and gene therapy (such as CAR-T); Except subjects with evidence that previous allogeneic cell and gene therapy products (such as CAR-positive T cells and CAR transgenes) in the subject have been below the lower limit of detection;\n* Previously received allogeneic hematopoietic stem cell transplantation;\n* Previously received gene therapy;\n* Donor specific antibody (DSA) positive subjects will be excluded;\n* Severe underlying diseases;\n* Hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C virus ribonucleic acid (HCV RNA) or human immunodeficiency virus antibody (HIV-Ab) positive;\n* Presence of other serious pre-existing medical conditions that may limit patient participation in the study. Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study.","ALL","18 Years",{"count":92,"type":93},42,"ESTIMATED","INTERVENTIONAL",[96],"PHASE1","This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed\u002Frefractory B-cell non-Hodgkin lymphoma.",[99,100],"Relapsed B-cell Non-Hodgkin Lymphoma","Refractory B-cell Non-Hodgkin Lymphoma",[102,103],"Relapsed B-cell non-Hodgkin lymphoma","Refractory B-cell non-Hodgkin lymphoma","2025-03-20",{"date":106,"type":107},"2025-03-25","ACTUAL",{"date":109,"type":107},"2024-03-14",{"date":111,"type":93},"2028-09",{"name":5,"class":6},3]